Anna L. Goodman

University College London - Department of Infection

Gower Street

London, WC1E 6BT

United Kingdom

SCHOLARLY PAPERS

5

DOWNLOADS
Rank 415

SSRN RANKINGS

Top 415

in Total Papers Downloads

63,567

SSRN CITATIONS

4

CROSSREF CITATIONS

2

Scholarly Papers (5)

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Number of pages: 37 Posted: 01 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Siena - Institute of Global Health, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, Federal University of Sao Paulo, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of the Witwatersrand, Soweto Clinical Trials Centre, Soweto Clinical Trials Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, Setshaba Research Centre, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Wits Reproductive Health & HIV Institute (WRHI), University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Oxford Vaccine Group, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Bristol - Cellular and Molecular Medicine, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, Liverpool School of Tropical Medicine - Department of Clinical Sciences, AstraZeneca Pharmaceuticals, University of the Witwatersrand - South African Medical Research Council, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - South African Medical Research Council, University of the Witwatersrand - South African Medical Research Council, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Oxford - Centre for Vaccinology and Tropical Medicine, AstraZeneca Pharmaceuticals, Braziland Hospital São Rafael - Escola Bahiana de Medicina e Saúde Pública, Universidade Federal do Rio Grande do Norte (UFRN), University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - Perinatal HIV Research Unit, Setshaba Research Centre, University of Oxford - Oxford Vaccine Group, Hospital Quinta D'OR, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Hospital Universitário de Santa Maria, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Universidade Federal do Rio Grande do Sul, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, University of Cambridge - Department of Medicine, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine and Independent
Downloads 51,893 (31)
Citation 3

Abstract:

Loading...

2.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Number of pages: 40 Posted: 04 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Oxford - Big Data Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - The Jenner Institute, Public Health England - National Infection Service, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, UK Biocentre, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - Oxford Vaccine Group, University of Bristol - Cellular and Molecular Medicine, University of Oxford - The Jenner Institute, University of Oxford - Jenner Institute, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, Queen Elizabeth University Hospital, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Cambridge, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent and Independent
Downloads 10,148 (707)
Citation 25

Abstract:

Loading...

3.

Vaccine after Effects and Post-Vaccine Infection in a Real World Setting: Results from the COVID Symptom Study App

Number of pages: 26 Posted: 04 Mar 2021
King's College London - Department of Twin Research and Genetic Epidemiology, King's College London - School of Biomedical Engineering & Imaging Sciences, Zoe Global Limited, Zoe Global Limited, Zoe Global Limited, King's College London - Department of Twin Research and Genetic Epidemiology, University College London, Harvard University - Harvard Medical School, Harvard University - Harvard Medical School, Massachusetts General Hospital - Center for Genomic Medicine, King's College London - School of Biomedical Engineering & Imaging Sciences, King's College London, King's College London - School of Biomedical Engineering & Imaging Sciences, King's College London - School of Biomedical Engineering & Imaging Sciences, King's College London - School of Biomedical Engineering & Imaging Sciences, King's College London - School of Biomedical Engineering & Imaging Sciences, Harvard University - Harvard Medical School, King's College London - Department of Twin Research and Genetic Epidemiology, King's College London - Division of Biomedical Engineering and Imaging Sciences, King's College London - Department of Twin Research and Genetic Epidemiology, University of Nottingham, University College London - Department of Infection, Harvard University - Harvard Medical School, Zoe Global Limited, Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK, King's College London - School of Biomedical Engineering & Imaging Sciences and King's College London - Department of Twin Research and Genetic Epidemiology
Downloads 829 (41,327)

Abstract:

Loading...

COVID-19; vaccination; Phase IV trial; Pfizer-BioNTech; Oxford/AstraZeneca; BNT162b2; ChAdOx1 nCoV-19

4.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

Number of pages: 39 Posted: 19 Apr 2021
University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, NIHR Imperial Clinical Research Facility, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University College London - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Oxford Vaccine Group, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, NIHR Guy's and St Thomas' Biomedical Research Centre, Imperial College London - Department of Infectious Disease, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Oxford University Hospitals NHS Foundation Trust, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Department of Paediatrics, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Imperial College London - Department of Infectious Disease, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Imperial College London - Department of Medicine, Guy's and St Thomas' NHS Foundation Trust - Harrison Wing, University of Oxford - The Jenner Institute and Independent
Downloads 608 (62,109)
Citation 2

Abstract:

Loading...

5.

Demographics and Outcomes of COVID-19 Medicines Delivery Units Across 4 UK Centres During the Initial B1.1.529 Omicron Epidemic: A Service Evaluation.

Number of pages: 16 Posted: 16 Jun 2022
London School of Hygiene & Tropical Medicine, Government of the United Kingdom - University College London Hospital, Guys and St Thomas’ Hospitals NHS Foundation Trust, Dept Infection, Immunity & Cardiovascular Disease, University of Sheffield, Infection Research Group, Hull University Teaching Hospitals NHS Foundation Trust, Government of the United Kingdom - University College London Hospital, University Hospital Lewisham, 5. Dept of Infectious Diseases & Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Infection Research Group, Hull University Teaching Hospitals NHS Foundation Trust, King's College London - Centre for Rheumatic Disease, Guys and St Thomas’ Hospitals NHS Foundation Trust, Infection Research Group, Hull University Teaching Hospitals NHS Foundation Trust, affiliation not provided to SSRN, Dept Infection, Immunity & Cardiovascular Disease, University of Sheffield, Infection Research Group, Hull University Teaching Hospitals NHS Foundation Trust, University College London - Department of Infection and London School of Hygiene & Tropical Medicine - Department of Clinical Research
Downloads 89 (386,037)

Abstract:

Loading...

COVID-19, molnupiravir, sotrovimab